In conclusion, the findings of the current study yield increasing awareness that a second trial of CAB discontinuation should be attempted in well-selected patients with prolactinomas who display normal PRL levels and tumor remnant <1 cm at low doses (≤1 mg/week). This evidence concerns the gene PRL and neoplasm.